Australia's largest stock trading and investment forum Australia's #1 stock forum

DXB

7.37%

51.0¢ dimerix limited

Great post!!Great days ahead for DXB :)IMHODYOR

First 59 Last

Share
Profile

Follow
Taipan88888

2,017 Posts.

204

04/01/24

08:04

Post #: 71718145
Share

Originally posted by vintage: ↑

Your attempts to spread negative innuendo are going from bad to worse - ill-informed and half-baked at best.

Your comments re Advanz are ridiculous for 2 reasons. One is that big pharmas are successful because they are astute and prudent and do not sloppily 'give away' $10M on a wing and a prayer. They have tight due diligence protocols and it is these protocols - 'not suck it and see and who cares if we blow $10M' - that determine their investments. Secondly, due to the agreed milestones, they have far more exposure than the $10M, if those milestones are met.

Your comments re the data are equally absurd. It is not 'having data' that is important. Its how you interpret it and how you calculate the economic and health benefits implicit in the data. Advanz have an army of scientists, medicos and promotional experts at their disposal - resources you could only dream about. They have voted with their feet. You haven't. That is your right but I know whose path I prefer.

Next, your aspersions against the management for not publishing the p-values and standard errors are just plain wrong. They are provided in multiple announcements - including those on 24 Feb 2022 and 29 Mar 2022 and in the presentation at the Bio International Convention 6 June 2023.

Finally, getting your nickers in a knot over the p-values and standard errors is a red herring. You don't have to be Einstein to know that a small sample (as in most Phase 1 and 2 trials) is going to have very high p-values and standard errors. But that is irrelevant. Phase 2 studies are for determining 'safety' and çlinical significance', not statistical significance. That is what Phase 3 is for - to demonstrate BOTH clinical and statistical significance.

The beauty of the Phase 2a trial was that it demonstrated both clinical significance and safety. We know the drug works - and by how much it works on a statistically insignificant'' population of 7. What we now need to know, is will it work as well - if not better - on a statistically significant'' population of 74.

And remember, 'statistical significance' is not a positive in and of itself. It is quite possible, for instance, to have very low p-value (i.e. high statistical significance) for clinical benefits that are negligible and not even worth pursuing.

You need both proofs - clinical and statistical - but it is a red herring to say you need the latter in Phase 2. If you had it, in effect, you would not need Phase 3.

Expand

Great post!!
Great days ahead for DXB
IMHO
DYOR

DXB Price at posting: 24.0¢ Sentiment: Buy Disclosure: Held
4 Upvote

0 Great analysis

Reply

Top Stories

AI stocks: What to expect in 2024-25

BYH

Bryah gains $408K government rebate for work on copper target Narracoota

Talking the US election, the spectre of Trump and what's hot on the ASX200: Wealth Within

IVR

Investigator Resources hits 8m @ 1.06% copper on-site Stuart Shelf JV project acreage

WC8

Leia pegmatite pulls up recoveries of 84% lithium for Wildcat in WA

There are more pages in this discussion • 19 more messages in this thread...

First 59 Last

Add DXB (ASX) to my watchlist

(20min delay)
Last 51.0¢		Change 0.035(7.37%)		Mkt cap ! $280.6M

Open	High	Low	Value	Volume
47.5¢	54.0¢	47.5¢	$3.360M	6.544M

Buyers (Bids)

No.	Vol.	Price($)
2	25428	51.0¢

Sellers (Offers)

Price($)	Vol.	No.
51.5¢	15478	1

View Market Depth

No.	Vol.	Price($)
2	25428	0.510
9	271116	0.505
3	245876	0.500
3	501512	0.495
4	56490	0.490

Price($)	Vol.	No.
0.515	15478	1
0.520	190972	5
0.525	188385	5
0.530	265966	8
0.535	125000	2

Last trade - 16.10pm 16/07/2024 (20 minute delay)

DXB (ASX) Chart

Great post!!Great days ahead for DXB :)IMHODYOR

AI stocks: What to expect in 2024-25

Bryah gains $408K government rebate for work on copper target Narracoota

Talking the US election, the spectre of Trump and what's hot on the ASX200: Wealth Within

Investigator Resources hits 8m @ 1.06% copper on-site Stuart Shelf JV project acreage

Leia pegmatite pulls up recoveries of 84% lithium for Wildcat in WA

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Great post!!Great days ahead for DXB :)IMHODYOR

Top Stories

AI stocks: What to expect in 2024-25

Bryah gains $408K government rebate for work on copper target Narracoota

Talking the US election, the spectre of Trump and what's hot on the ASX200: Wealth Within

Investigator Resources hits 8m @ 1.06% copper on-site Stuart Shelf JV project acreage

Leia pegmatite pulls up recoveries of 84% lithium for Wildcat in WA

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News